Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.24 and traded as low as $0.2296. Northwest Biotherapeutics shares last traded at $0.2327, with a volume of 2,694,391 shares traded.
Northwest Biotherapeutics Price Performance
The firm has a market cap of $387.08 million, a P/E ratio of -0.01 and a beta of -0.74. The stock has a 50 day moving average of $0.21 and a 200 day moving average of $0.24.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Featured Stories
- Five stocks we like better than Northwest Biotherapeutics
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
